How Does Wegovy Work?

Wegovy is a prescription medication containing semaglutide.

Semaglutide belongs to a class of medications called GLP-1 receptor agonists.

GLP-1 stands for glucagon-like peptide-1.

Your body naturally produces GLP-1, particularly after you eat. It acts as a signaling hormone involved in:

• Appetite
• Satiety
• Blood sugar regulation
• Insulin secretion
• Glucagon secretion
• Digestion

Natural GLP-1 doesn't remain active for very long.

Semaglutide was designed to activate the same GLP-1 receptor while remaining active much longer, which allows Wegovy to be administered once weekly.

One of Wegovy's most important effects occurs in the systems that regulate appetite.

GLP-1 receptors are found in areas of the brain involved in hunger and food intake.

By activating these receptors, semaglutide can increase satiety, or the feeling that you've had enough to eat.

People taking Wegovy may notice that they:

• Get hungry less often
• Feel satisfied after smaller meals
• Stay full longer
• Have less interest in snacking
• Find it easier to stop eating

This can make eating fewer calories feel considerably different from traditional dieting.

Instead of constantly trying to ignore hunger, the biological drive to eat may become less intense.

It can.

Clinical research has found that semaglutide can influence more than physical hunger.

Studies examining appetite and eating behavior have found reductions in:

• Hunger
• Food cravings
• Desire for certain foods
• Overall energy intake

Some patients describe this as experiencing less “food noise” — the persistent thoughts about food, eating, or the next meal.

“Food noise” isn't a formal medical diagnosis, but the phrase describes an experience many patients recognize.

Semaglutide's effects on appetite and reward-related eating may help explain why some people notice these thoughts becoming less prominent during treatment.

Semaglutide can delay gastric emptying, meaning food may leave the stomach more slowly.

This can contribute to feeling full after eating.

However, it's important not to reduce Wegovy's entire mechanism to “food stays in your stomach longer.”

Semaglutide's effects on appetite and weight involve multiple systems, including signaling between the digestive tract and brain.

Research also suggests that the effect of long-acting GLP-1 medications on gastric emptying can become less pronounced with continued exposure.

So appetite regulation — not simply slowing digestion — is a major part of how Wegovy supports long-term weight management.

GLP-1 receptors also play an important role in blood glucose regulation.

When blood glucose is elevated, semaglutide can help increase insulin secretion.

Insulin helps move glucose from the bloodstream into cells.

Semaglutide can also reduce secretion of glucagon, a hormone that signals the liver to release glucose.

Importantly, these effects are largely glucose-dependent.

That means the medication's effects on insulin secretion become stronger when blood sugar is elevated and diminish as glucose levels fall.

This is one reason GLP-1 medications have also been extensively studied in people with type 2 diabetes.

Not directly.

Wegovy isn't a traditional “fat burner.”

It doesn't simply enter the body and cause stored fat to disappear.

Instead, it helps reduce appetite and calorie intake.

When someone consistently consumes less energy than their body uses, the body begins drawing from stored energy — including body fat.

Over time, this energy deficit produces weight loss.

So a simplified version looks like this:

The biology is more complicated, but that's the basic idea.

Semaglutide can produce meaningful reductions in calorie intake.

In a controlled study of adults with obesity, participants receiving once-weekly semaglutide consumed approximately 35% fewer calories during an unrestricted test meal after 20 weeks compared with participants receiving placebo.

Participants also reported less hunger, fewer food cravings, and better control over eating.

That helps explain why GLP-1 treatment can feel different from simply being told to “eat less.”

The medication can change some of the biological signals influencing how much someone wants to eat in the first place.

Results vary considerably between individuals.

One of the major clinical trials of Wegovy was STEP 1, which included nearly 2,000 adults with overweight or obesity without diabetes.

After 68 weeks:

• Semaglutide 2.4 mg: approximately 14.9% average body-weight reduction
• Placebo: approximately 2.4% average reduction

Participants also received lifestyle interventions.

More than half of participants receiving semaglutide lost at least 15% of their starting body weight, although individual results varied.

Some people lose considerably more or less than the average.

Semaglutide begins acting in the body after treatment starts, but weight loss isn't immediate.

Some people notice appetite changes relatively early.

Changes on the scale generally develop progressively over weeks and months.

Wegovy is also intentionally started at a low dose and gradually increased.

The typical escalation begins at 0.25 mg once weekly before progressing through higher doses.

The lower starting doses give the body time to adjust and can help improve gastrointestinal tolerability.

That means the first month isn't necessarily supposed to produce someone's maximum weight-loss response.

Gastrointestinal side effects are among the most common effects of GLP-1 medications.

These can include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal discomfort

Starting immediately at a high dose could make these symptoms more difficult to tolerate.

Gradual dose escalation allows the gastrointestinal system time to adjust to semaglutide.

Clinical research shows that many gastrointestinal side effects are most noticeable during or shortly after dose increases and often become less prominent as treatment continues.

Weight loss doesn't usually continue indefinitely.

As body weight decreases, the amount of energy the body requires also changes.

Eventually, many patients reach a weight plateau, where weight becomes relatively stable.

That doesn't necessarily mean Wegovy suddenly stopped affecting appetite.

Instead, energy intake and energy expenditure may have reached a new balance.

Weight-management treatment is generally focused not only on losing weight but also on maintaining the weight that was lost.

Wegovy doesn't permanently remove the biological tendency toward weight gain.

When treatment stops, semaglutide gradually leaves the body and its appetite-regulating effects diminish.

In the STEP 1 trial extension, participants regained a substantial portion of the weight they had previously lost during the year after semaglutide was discontinued.

This doesn't mean everyone will regain the same amount.

But it demonstrates that obesity is often a chronic condition, and the biological pressures influencing appetite and body weight can return when treatment ends.

Nutrition, physical activity, behavioral habits, and long-term treatment planning all matter for maintaining results.

Wegovy and Ozempic both contain semaglutide, but they are separate prescription products.

They have different labeled indications and dosing schedules.

Wegovy is specifically used for chronic weight management in eligible patients and also has certain cardiovascular-related indications.

Ozempic is primarily used in people with type 2 diabetes and has additional labeled indications in appropriate patients.

Although they contain the same active ingredient, the brand names shouldn't automatically be treated as interchangeable.

Wegovy works by activating GLP-1 receptors involved in appetite, fullness, food intake, digestion, and blood sugar regulation.

Its active ingredient, semaglutide, can make people feel less hungry and more satisfied after smaller amounts of food.

That often leads to a meaningful reduction in calorie intake.

Wegovy doesn't directly burn body fat.

Instead, it changes some of the biological signals that can make maintaining a calorie deficit difficult.

Over time:

Less hunger + greater satiety + reduced calorie intake can lead to significant weight loss.

Clinical trials have demonstrated average weight reductions of around 15% over 68 weeks with semaglutide 2.4 mg alongside lifestyle intervention, although individual results vary.

At Luma Meds, eligible patients can discuss their weight-loss goals and available GLP-1 treatment options with a licensed healthcare provider to determine which approach may be appropriate for their individual needs.